Randomized Phase II Study Of Immunization With Mage-3/Melan-A/gp100/NA17 Peptide-Pulsed Autologous PBMC And rhIL-12 With Or Without Low Dose IL-2 In Patients With Metastatic Melanoma

Trial Profile

Randomized Phase II Study Of Immunization With Mage-3/Melan-A/gp100/NA17 Peptide-Pulsed Autologous PBMC And rhIL-12 With Or Without Low Dose IL-2 In Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2012

At a glance

  • Drugs Interleukin-12 (Primary) ; Melanoma vaccine (Primary) ; Interleukin-2
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 May 2007 Status change
    • 15 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top